This is my fourth Savara Inc. (NASDAQ: SVRA ) article, following 07/2025's "Savara: Repairing The Molbreevi aPAP Opportunity After RTF." Savara is a 1-trick pony with its Molbreevi in the treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) beingWriting under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades ...